Lerociclib
Small moleculeexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Jun 2, 2021 (NCT05337657)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinase 6INHIBITOR
CDK6 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)N1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1- Mol. weight
- 474.61 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3904602 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05712941 | Phase 3 | Apr 18, 2023 | EQRx, Inc., European Network for Gynaecological Oncological Trial, GOG Foundation, Inc. |
| NCT05860582 | Phase 1 | Sep 14, 2022 | Beijing Boren Hospital, Genor BioPharma Co., Ltd. |
| NCT05851014 | Phase 3 | Jan 14, 2022 | Fudan University, Genor BioPharma Co., Ltd. |
| NCT05085002 | Phase 2 | Nov 30, 2021 | EQRx, Inc. |
| NCT05054751 | Phase 3 | Oct 15, 2021 | Chinese Academy of Medical Sciences, Genor BioPharma Co., Ltd. |
| NCT05337657 | Phase 1 | Jun 2, 2021 | Fudan University, Genor BioPharma Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genor BioPharma Co., Ltd. | For profit | 4 | 4 | 2 | 2021 |
| EQRx, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Fudan University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Beijing Boren Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2023 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2023 |
7 organizations
Page 1 / 1